| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… |
Trial sites expanded: 89 -> 111 locations |
| 2026-06-06 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites reduced: 278 -> 271 locations |
| 2026-05-15 | NCT06057402 Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) |
Trial sites expanded: 15 -> 28 locations |
| 2026-05-15 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites expanded: 131 -> 279 locations |
| 2026-05-15 | NCT06215118 A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and… |
Trial sites expanded: 21 -> 43 locations |
| 2026-05-15 | NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… |
Trial sites expanded: 39 -> 89 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07637578 A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory… | Phase 2 | Not Yet Recruiting |
| 2026-05-29 | NCT07612787 A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Multiple Myeloma | Recruiting |
| Phase 3 | |||
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in… | Multiple Myeloma | Recruiting |
| NCT06918002 | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of… | Multiple Myeloma, Newly Diagnosed | Recruiting |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… | Multiple Myeloma | Recruiting |
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… | Multiple Myeloma | Recruiting |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple… | Multiple Myeloma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06015542 | Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | Multiple Myeloma | Recruiting |
| NCT06207799 | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With… | Multiple Myeloma | Recruiting |
| NCT06711705 | Elranatamab in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT07454382 | A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT06832865 | ELISA in Relapsed/Refractory MM | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT06138275 | Elranatamab in R/R Multiple Myeloma | Refractory Multiple Myeloma | Recruiting |
| NCT07382739 | A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in… | Phase 2 | Recruiting |
| NCT06974786 | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable… | Multiple Myeloma, Newly Diagnosed | Recruiting |
| NCT07524634 | Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed… | Amyloid Light-chain Amyloidosis | Not Yet Recruiting |
| NCT04649359 | MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With… | Multiple Myeloma | Active, Not Recruiting |
| NCT06282978 | Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to… | Multiple Myeloma in Relapse | Active, Not Recruiting |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed… | Myeloma Multiple | Not Yet Recruiting |
| NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory… | Multiple Myeloma (MM) | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | AL Amyloidosis | Recruiting |
| NCT06988488 | A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and… | Multiple Myeloma | Recruiting |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With… | Multiple Myeloma | Recruiting |
| Phase 1 | |||
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene… | Multiple Myeloma | Recruiting |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in… | Multiple Myeloma (MM) | Recruiting |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in… | Multiple Myeloma | Recruiting |